# Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

> **NCT04732494** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 125 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Tislelizumab
- **BIOLOGICAL:** Ociperlimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04732494
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-31
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-12-26
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04732494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04732494, "Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04732494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*